NEW YORK (GenomeWeb News) – Life Technologies said today that it has entered a partnership with Chinese biotech company Sino Biological for global product distribution and development of reagents for proteomic research.
Under the agreement, Life Tech will distribute Sino's portfolio of recombinant proteins, antibodies, and ELISA kits. The companies will also collaborate on developing new products for applications including flow cytometry and imaging.
In a statement, Siddhartha Kadia, Life Tech president for Greater China, said that through the deal the company would offer Sino's more than 6,000 human-derived proteins and antibodies.
"The collaboration presents a tremendous opportunity to offer a robust proteomics portfolio to meet customer needs in this highly dynamic global market," Life Tech Chairman and CEO Gregory Lucier said. "Through this collaboration we plan to leverage our strong brands, worldwide commercial reach and technology support with Sino Biological's world leading technologies to develop solutions for scientists worldwide who are tackling important healthcare challenges such as cancer, diabetes, and heart disease."
Life Tech's Greater China business currently employs roughly 1,000 people and maintains 10 sales offices and three distribution centers through mainland China and Taiwan.
Financial and other terms of the agreement were not disclosed.